EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ascletis Pharma's Enterprise Value is HK$-1,288.31 Mil.
Ascletis Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-178.64 Mil. Therefore, Ascletis Pharma's EV-to-FCF for today is 7.21.
The historical rank and industry rank for Ascletis Pharma's EV-to-FCF or its related term are showing as below:
HKSE:01672'
s EV-to-FCF Range Over the Past 10 Years
Min: -41.77 Med: 0.37 Max: 7.15
Current: 7.15
During the past 8 years, the highest EV-to-FCF of Ascletis Pharma was 7.15. The lowest was -41.77. And the median was 0.37.
HKSE:01672's EV-to-FCF is ranked better than 51.57% of 382
companies
in the Biotechnology industry
Industry Median: 7.97
vs HKSE:01672: 7.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Ascletis Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ascletis Pharma's EV-to-FCF
For the Biotechnology subindustry, Ascletis Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's EV-to-FCF falls into.
Ascletis Pharma's current Enterprise Value is HK$-1,288.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-178.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ascletis Pharma's PE Ratio for today is calculated as:
Ascletis Pharma's share price for today is HK$1.21.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.148.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascletis Pharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Ascletis Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01672 has been successfully added to your 